Search

Displaying results 1371 - 1380 of 8696 in total
  1. Drug

    Fluciclovine (18F)

    go.drugbank.com/drugs/DB13146
    ApprovedInvestigational

    [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]

  2. Target

    Leucine-rich repeat-containing G protein-coupled receptor 5

    go.drugbank.com/bio_entities/BE0010835
    TargetHumans

    Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle.

    Polypeptides: Leucine-rich repeat-containing G protein-coupled receptor 5Synonyms: G protein-coupled receptor 49, G protein-coupled receptor 67
  3. Indication

    Epilepsy, Primary Generalized Tonic-Clonic Seizures

    go.drugbank.com/conditions/DBCOND0054806
    Drugs: Perampanel · Topiramate
    Synonyms: Grand mal, Grand mal fit
  4. Drug

    Carbamide peroxide

    go.drugbank.com/drugs/DB11129
    ApprovedInvestigational

    It may also alter enamel surface morphology via enamel mineral loss and surface roughening [A32336]. … Some adverse effects of carbamide peroxide as a dental bleaching agent include dentin sensitivity and/or gingival irritation led by unstable and reactive H+ free radicals and low pH from prolonged use.

  5. Drug

    Imatinib

    go.drugbank.com/drugs/DB00619
    ApprovedInvestigational

    The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
  6. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    [A191910] As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery … [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  7. Drug

    Nabilone

    go.drugbank.com/drugs/DB00486
    ApprovedInvestigational

    inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others [A32824]. … While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsProducts: Ran-nabilone
  8. Indication

    Deficiency of the interleukin-1 receptor antagonist

    go.drugbank.com/conditions/DBCOND0008480
    Drugs: Anakinra · Rilonacept
    Synonyms: Deficiency of interleukin-1 receptor antagonist, Interleukin-1 receptor antagonist deficiency
  9. Drug

    Ethylenediamine

    go.drugbank.com/drugs/DB14189
    Approved

    Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products. … Sensitivity to ethylenediamine may be identified with a clinical patch test.

  10. Drug

    Dutasteride

    go.drugbank.com/drugs/DB01126
    ApprovedInvestigational

    Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to … Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates